Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

With a median follow-up of 66.8 months, nivolumab plus ipilimumab demonstrated continued overall survival(OS) benefit versus chemotherapy in all randomly assigned patients (5-year OS rates, 14% v 6%; hazard ratio[HR], 0.74 [95% CI, 0.62 to 0.88]); similar benefit was observed regardless of tumor histology.

在中位随访66.8个月的情况下，纳武利尤单抗加伊匹木单抗在所有随机分配的患者中显示出持续的总生存（OS）获益，与化疗相比（5年OS率，14%对比6%；风险比[HR]，0.74 [95%置信区间，0.62至0.88]）；无论肿瘤组织学如何，都观察到类似的获益。

Of biomarker-evaluable patients treated with nivolumab plus ipilimumab (n = 242), high baseline monocytic myeloid-derived suppressor cell (M-MDSC) levels correlated with worse OS versus low M-MDSC levels (HR, 1.25 [95% CI, 1.09 to 1.43]).

在使用纳武利尤单抗联合伊匹木单抗治疗的生物标志物可评估患者中（n = 242），高基线单核细胞来源的髓系抑制细胞（M-MDSC）水平与较差的总生存期（OS）相关，与低M-MDSC水平相比（风险比，1.25 [95% 置信区间，1.09至1.43]）。

After adjusting for 24% of patients in the chemotherapy arm who received subsequent immunotherapy, nivolumab plus ipilimumab demonstrated continued OS benefit versus chemotherapy (HR, 0.64 [95% CI, 0.53 to 0.78]).

在调整了化疗组中有24%的患者后续接受了免疫治疗后，纳武利尤单抗联合伊匹木单抗与化疗相比，总生存期（OS）的益处持续存在（风险比，0.64 [95% 置信区间，0.53至0.78]）。

No new safety signals were observed.

未观察到新的安全信号。

These results demonstrate long-term, durable clinical benefit with nivolumab plus ipilimumab versus chemotherapy, which continued to be preserved even after treatment-switching adjustment in the chemotherapy arm.

这些结果表明，与化疗相比，纳武利尤单抗联合伊匹木单抗具有长期且持久的临床获益，即使在化疗组进行治疗调整后，这种获益仍然得以保持。

Exploratory analyses suggested greater benefit with nivolumab plus ipilimumab in the low M-MDSC subgroup.

探索性分析表明，在低M-MDSC亚组中，纳武利尤单抗联合伊匹木单抗的疗效更佳。

These results further support first-line nivolumab plus ipilimumab as standard of care for unresectable PM.

这些结果进一步支持将纳武利尤单抗联合伊匹木单抗作为不可切除性PM一线治疗的标准治疗。